BRD4 and neoplasm: This study also employed XMD8-92 to demonstrate inhibition of growth of PDAC tumour xenografts in combination with ERK1/2i; given the dual-ERK5/BRD4 activity of XMD8-92 it will be critical to see these experiments repeated with a selective ERK5i that does not have BRD4 activity (for more detail see below and Figure 4) (Vaseva et al., 2018).